These mutations make cells sensitive to EGFR tyrosine kinase inhibitors (TKIs), which have revolutionized treatment paradigms in advanced NSCLC (Tsuboi et al., 2023). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.